Incyte Corporation INCY

FOSTER CITY, Calif. & WILMINGTON, Del., September 25, 2026--Mirum and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva

The Food and Drug Administration’s target date is Saturday, September 26, for zilurgisertib, a once-daily pill for fibrodysplasia ossificans progressiva, or FOP, in patients 12 and older.

Incyte has delivered a strong multi year share-price run, so the obvious follow up is whether the current valuation is still grounded in the cash the business is expected to generate. With investors weighing fresh product news against a higher starting price, the question is how much of Incyte's future cash flows are already embedded in today's quote. Over the past 3 years the stock has gained 110.9%, which puts pressure on investors to judge whether the cash flow outlook has risen enough to...

Incyte (NasdaqGS: INCY) plans to present new clinical data on its inflammation and autoimmunity portfolio at the upcoming EADV Congress. The presentation will spotlight updates for Opzelura, ruxolitinib cream, across immune mediated skin diseases studied in recent dermatology trials. Incyte will also feature new findings on povorcitinib, reflecting progress across multiple dermatological indications under investigation. These fresh EADV data drops on Opzelura and povorcitinib only tell part...

Morgan Stanley highlights high-risk, high-reward biotech stocks poised for massive upside following key upcoming clinical readouts.

Incyte is gaining momentum, recently outperforming the biotech sector and keeping analysts broadly positive on the stock.

Dow Jones tech titan Amazon stock is battling with a key support level and approaching multiple new buy points.

Incyte's (INCY) colorectal cancer or CRC programs remain "risky and more long-term," RBC Capital Mar

WILMINGTON, Del., September 22, 2026--Incyte Data at the 2026 EADV Congress Underscore the Breadth of Incyte’s Inflammation and Autoimmunity Portfolio

Merck, Mirum, Incyte and Grail are in focus this week as investors await key FDA decisions and a regulatory review involving treatments for lung disease, a rare bone disorder and cancer detection.

Independent biopharmaceutical company Specialised Therapeutics (ST) today announced an expansion of its existing partnership with Incyte Biosciences International, an affiliate of Incyte (NASDAQ: INCY), to commercialise, distribute, and register ruxolitinib cream (registered as Opzelura® in the U.S. and European Union) in Australia.

Robinhood stock surged in an end-of-week crypto rally. SpaceX is testing an aggressive entry. They lead five stocks near buy points.